SAN MATEO, CA -- (MARKET WIRE) -- September 18, 2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A today reported interim data showing that the addition of ZADAXIN® to standard dacarbazine (DTIC) chemotherapy, with or without interferon alpha in patients, with stage IV, the most advanced form of malignant melanoma, achieved double the overall tumor response as compared to the control group. Additional results from this trial, including preliminary survival data for the first four arms of this trial, are expected prior to the end of the year.
